Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06537713
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-07-31
Brief Title:
Diagnostic Role of Serum Testican and Ubiquitin Levels in Patients With Head Trauma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Diagnostic Role of Serum Testican and Ubiquitin Levels in Patients With Head Trauma
Status:
COMPLETED
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
We aimed to determine if testican-1 and ubiquitin can serve as early indicators for diagnosing worsening clinical course presence of intraparenchymal pathology and mortality in patients with moderate traumatic brain injury
Detailed Description:
The study specifically included patients over 18 years of age with moderate TBI GCS 9-13 who provided informed consent The control group consisted of healthy individuals without any disease who voluntarily participated in the study Patients with moderate TBI were divided into two groups those with intracranial pathology Subdural hemorrhage epidural hemorrhage subarachnoid hemorrhage intraparenchymal hemorrhage and contusion and those without Treatment was initiated according to ATLS in patients with moderate TBI and blood samples taken at the time of admission to the emergency department were placed in Ethylenediaminetetraacetic acid EDTA tubes The relationship between the patients clinical scoring GCS ISS and AIS brain CT results and mortality status with testican-1 and ubiquitin levels was compared
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None